Net Loss Per Share Attributable to Common Stockholders (Tables)

9 Months Ended

Sep. 30, 2024

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Numerator:
Net loss	$	(48,548)	$	(83,940)	$	(169,193)	$	(286,429)
Denominator:
Weighted average common shares outstanding	99,835,707		97,227,070		99,050,167		61,580,296
Less: Weighted-average common shares subject to repurchase	0		(354,323)		(76,649)		(442,191)
Weighted-average common shares outstanding, basic and diluted	99,835,707		96,872,747		98,973,518		61,138,105
Net loss per share attributable to common stockholders, basic and diluted	$	(0.49)	$	(0.87)	$	(1.71)	$	(4.68)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:

	As of September 30,
	2024	2023
Outstanding options to purchase common stock	14,071,995	8,704,462
Unvested RSUs outstanding	1,204,470	2,183,413
Unvested PSUs expected to vest	178,404	—
Outstanding options to purchase common stock assumed upon acquisition of ValenzaBio	55,311	1,249,811
Common stock subject to repurchase	—	295,803
ESPP	108,048	—
Total	15,618,228	12,433,489